OBJECTIVES: Human papillomavirus (HPV) infections are highly prevalent sexually transmitted infections, notably associated with various cancers. This study analyses the health and economic impacts of HPV-associated diseases in the Czech Republic and evaluates the cost-effectiveness of a catch-up vaccination program. METHODS: Utilizing a Markov multistate model, the study assesses the lifetime impacts and costs related to HPV infections. Cohorts of ages 15-21 were simulated to assess the impact of catch-up vaccination outside the 11-year-old age group. RESULTS: The total quality-adjusted life years (QALYs) for the female and male cohorts (together 119,362 individuals) were higher in the vaccination scenario compared to the non-vaccination scenario. The increase in QALYs was 122,246 and 200,852 respectively, when considering the actual vaccination rates. Across both cohorts, 329 cancer-related deaths were prevented. In the probabilistic sensitivity analysis for the female population, vaccination was the dominant strategy in 99.3% of iterations. In the male population, vaccination was the dominant strategy in 80.3% of iterations. The implementation of catch-up vaccination for the 15-21 age group significantly increased QALY gains and reduced life-years-lost (LYLs). In the female cohort, all analysed rates of catch-up vaccination were the dominant strategy, while in the male cohort, the incremental cost-effectiveness ratios (ICERs) remained consistently below 42,000 CZK/QALY. CONCLUSIONS: The catch-up vaccination program for 15-21-year-olds is cost-effective and can prevent a significant number of HPV-related cancers in both men and women.

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague nám Sítná 3105 Prague 272 01 Czech Republic

Department of Gynaecology and Obstetrics 1st Medical Faculty of Charles University General University Hospital Prague Prague Czech Republic

Institute of Preventive Medicine Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Research Institute for Biomedical Science Hradec Kralove Czech Republic

Zobrazit více v PubMed

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F, El, et al. A review of human carcinogens—part B: biological agents. Lancet Oncol. 2009;10(4):321–2. PubMed

Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008;26:K17–28. PubMed PMC

De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626–36. PubMed

Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86. PubMed

Ting J, Kruzikas DT, Smith JS. A Global Review of Age-Specific and overall prevalence of cervical lesions. Int J Gynecol Cancer. 2010;20(7):1244–9. PubMed

de Bruni LAGSBMMCJGDMJBF. SS. Human Papillomavirus and Related Diseases Report WORLD. 2023. Available from: www.hpvcentre.net.

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of Cancer 2013. JAMA Oncol. 2015;1(4):505. PubMed PMC

de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. PubMed PMC

Castellsagué X, Mena M, Alemany L. In. Epidemiology of HPV-Positive tumors in Europe and in the World. 2017. pp. 27–35. PubMed

Halec G, Holzinger D, Schmitt M, Flechtenmacher C, Dyckhoff G, Lloveras B, et al. Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer. 2013;109(1):172–83. PubMed PMC

Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978–2008. Int J Cancer. 2012;130(5):1168–73. PubMed

Attner P, Du J, Näsman A, Hammarstedt L, Ramqvist T, Lindholm J, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer. 2010;126(12):2879–84. PubMed

Clark M, Jembere N, Kupets R. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts. Prev Med (Baltim). 2021;150:106641. PubMed

Dehlendorff C, Baandrup L, Kjaer SK. Real-world effectiveness of human papillomavirus vaccination against Vulvovaginal High-Grade Precancerous lesions and cancers. JNCI: J Natl Cancer Inst. 2021;113(7):869–74. PubMed PMC

Gavriatopoulou M, Ntanasis-Stathopoulos I, Kyriazoglou A, Liontos M, Dimopoulos MA. Current trends in the management and prevention of human papillomavirus (HPV) infection. JBUON. 2020;25(3):1281–5. PubMed

Hardt K, Bonanni P, King S, Santos JI, El-Hodhod M, Zimet GD, et al. Vaccine strategies: optimising outcomes. Vaccine. 2016;34(52):6691–9. PubMed

Jaworek H, Zborilova B, Koudelakova V, Brezinova J, Vrbkova J, Oborna I, et al. Prevalence of human papillomavirus infection in oocyte donors and women treated for infertility: an observational laboratory-based study. Eur J Obstet Gynecol Reprod Biol X. 2019;4:100068. PubMed PMC

Tachezy R, Smahelova J, Kaspirkova J, Salakova M. Human papillomavirus type-specific prevalence in the Cervical Cancer Screening Population of Czech Women. PLoS ONE. 2013;8(11):e79156. PubMed PMC

Rob F, Tachezy R, Pichlík T, Rob L, Kružicová Z, Hamšíková E, et al. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-another reason for HPV vaccination of boys. Dermatol Ther. 2017;30(1):e12435. PubMed

Jaworek H, Koudelakova V, Oborna I, Zborilova B, Brezinova J, Ruzickova D, et al. Prevalence and genotype distribution of human papillomavirus in Czech non-vaccinated heterosexual couples. Virol J. 2021;18(1):80. PubMed PMC

Dusek L. Očkování proti HPV a prevence karcinomu hrdla děložního. National Health Information System,Meeting of the PSP Health Committee [online] Available: https://www.psp.cz/sqw/hp.sqw?k=3206%26ido=1557%26td=22%26cu=25. 2023.

Daniel Mullins C, Onwudiwe NC, Branco de Araújo GT, Chen W, Xuan J, Tichopád A, et al. Guidance Document: global pharmacoeconomic model adaption strategies. Value Health Reg Issues. 2014;5:7–13. PubMed

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23. PubMed PMC

Simons JJM, Vida N, Westra TA, Postma MJ. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine. 2020;38(30):4687–94. PubMed

Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global Burden of Human Papillomavirus and Related diseases. Vaccine. 2012;30:F12–23. PubMed

Dusek L, Muzik J, Kubik M, Koptikova Jana, Zaloudik J, Vyzula R. Epidemiologie zhoubných nádorů v České republice. The national oncological registry (SVOD - System for Visualizing of Oncological Data) [online] Available: https://svod.cz. 2023.

Fronteira I, Oliveira da Silva M, Unzeitig V, Karro H, Temmerman M. Sexual and reproductive health of adolescents in Belgium, the Czech Republic, Estonia and Portugal. Eur J Contracept Reproductive Health Care. 2009;14(3):215–20. PubMed

Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197–206. PubMed PMC

Available. https://www.scitani.cz/vekova-struktura. 2021. CZSO, „Věková struktura, Sčítání 2021.

Suijkerbuijk AWM, Donken R, Lugnér AK, de Wit GA, Meijer CJLM, de Melker HE, et al. The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. Expert Rev Vaccines. 2017;16(4):361–75. PubMed

Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11. PubMed PMC

Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against Cancer. Vaccines (Basel). 2021;9(12):1413. PubMed PMC

Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine. 2009;27(35):4776–83. PubMed

Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang KL, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008;26:F46–58. PubMed

Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJLM, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350(may12 7):h2016–2016. PubMed PMC

Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205–16. PubMed PMC

Available. https://opendata.sukl.cz/?q=katalog/lek-13. 2023. STÁTNÍ ÚSTAV PRO KONTROLU LÉČIV. Otevřená data. LEK-13.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV vaccine against infection and Intraepithelial Neoplasia in Women. N Engl J Med. 2015;372(8):711–23. PubMed

Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38. PubMed PMC

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good practices Task Force. Value Health. 2022;25(1):10–31. PubMed

Dong L, Nygård M, Hansen BT. Sociodemographic correlates of Human Papillomavirus Vaccine Uptake: opportunistic and Catch-Up vaccination in Norway. Cancers (Basel). 2021;13(14):3483. PubMed PMC

Machida M, Inoue S. Patterns of HPV vaccine hesitancy among catch-up generations in Japan: a descriptive study. Vaccine. 2023;41(18):2956–60. PubMed

Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702. PubMed PMC

Cody P, Tobe K, Abe M, Elbasha EH. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis. 2021;21(1):11. PubMed PMC

Daniels V, Prabhu VS, Palmer C, Samant S, Kothari S, Roberts C, et al. Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. Hum Vaccin Immunother. 2021;17(7):1943–51. PubMed PMC

Simons JJM, Westra TA, Postma MJ. Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands. Prev Med Rep. 2022;28:101872. PubMed PMC

Kamenský V, Rogalewicz V, Gajdoš O, Donin G. Discrete event Simulation Model for cost-effectiveness evaluation of screening for asymptomatic patients with lower extremity arterial disease. Int J Environ Res Public Health. 2022;19(18):11792. PubMed PMC

Pöhlmann J, Russel-Szymczyk M, Holík P, Rychna K, Hunt B. Treating patients with type 2 diabetes Mellitus Uncontrolled on basal insulin in the Czech Republic: cost-effectiveness of IDegLira Versus iGlarLixi. Diabetes Therapy. 2019;10(2):493–508. PubMed PMC

Vocelka M, Haluska M, Mazel T, Lukacisinova A, Stefancikova I. Willingness to pay for Qaly in the Czech Republic between 2013 and 2017: a review. Value Health. 2017;20(9):A671–2.

Mahumud RA, Alam K, Keramat SA, Ormsby GM, Dunn J, Gow J. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: evidence from a systematic review. PLoS ONE. 2020;15(6):e0233499. PubMed PMC

Mauz PS, Schäfer FA, Iftner T, Gonser P. HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis. BMC Infect Dis. 2018;18(1):343. PubMed PMC

Matsuzaki H, Makiyama K, Hirai R, Suzuki H, Asai R, Oshima T. Multi-year effect of human papillomavirus vaccination on recurrent respiratory papillomatosis. Laryngoscope. 2020;130(2):442–7. PubMed

Boiron L, Joura E, Largeron N, Prager B, Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016;16(1):153. PubMed PMC

Available. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/human-papillomavirus-(hpv). 2022. Human Papillomavirus vaccines: World Health Organization position paper.

Gervais F, Dunton K, Jiang Y, Largeron N. Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend. BMC Public Health. 2017;17(1):283. PubMed PMC